Product logins

Find logins to all Clarivate products below.


Trauma Devices | Market Insights | Japan | 2024

The impact of the COVID-19 pandemic on the Japanese trauma device market was relatively lesser due to the urgent nature of the procedures involved. Going forward, market growth will be supported by favorable demographics and the increasing presence of domestic competitors. However, certain factors, such as the potential implementation of a reimbursement pricing system based on cost-effectiveness, slower introduction of high-priced devices compared to other mature global markets, and declining average selling prices due to biennial reimbursement cuts by the MHLW, will pose challenges to overall market growth.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for trauma devices in Japan from 2019 through 2032.

Related Medtech Insights Reports

Report
Sports Medicine Devices – Market Insights – Japan
Technological investments, adoption of premium-priced products, increased market awareness through educational programs, improved surgeon training, and high levels of sports participation will…
Report
Large-Joint Reconstructive Implants – Market Insights – Japan
Growth in large-joint reconstructive procedure volumes is being driven by favorable demographic trends and increased demand for innovative technologies. However, market expansion is partly…
Report
Trauma Devices – Market Insights – Japan
The Japanese trauma device market will experience marginal growth through 2034, primarily fueled by the adoption of innovative, premium-priced technologies. This upward trend is further supported…
Report
Cardiac Rhythm Management Devices – Market Insights – Japan
The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Japan
The Japanese GI endoscopy device market is projected to experience modest expansion through 2034. This growth is driven by favorable treatment and screening guidelines, as well as an aging…